Intermediate clinical endpoints: A bridge between progression-free survival and overall survival in ovarian cancer trials

Author： Matulonis Ursula A.   Oza Amit M.   Ho Tony W.   Ledermann Jonathan A.  

Publisher： Blackwell Publishing

E-ISSN： 1097-0142|121|11|1737-1746

ISSN： 0008-543X

Source： Cancer, Vol.121, Iss.11, 2015-06, pp. : 1737-1746

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Improving progression-free and overall survival in patients with cancer: a potential role for bisphosphonates

By Lipton Allan  

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 5, 2011-04 ,pp. : 749-762

Informa Healthcare

Access to resources Recommend Favorite

Missing Data and Censoring in the Analysis of Progression-Free Survival in Oncology Clinical Trials

By Denne J. S.   Stone A. M.   Bailey-Iacona R.   Chen T.-T.  

Journal of Biopharmaceutical Statistics, Vol. 23, Iss. 5, 2013-09 ,pp. : 951-970

Taylor & Francis Ltd

Access to resources Recommend Favorite

Relationship between response rates and median progression‐free survival in non‐Hodgkin's lymphoma: A meta‐analysis of published clinical trials

By  

Hematological Oncology (Electronic), Vol. 36, Iss. 1, 2018-02 ,pp. : 37-43

John Wiley & Sons Inc

Access to resources Recommend Favorite

Addition of bevacizumab to cetuximab with or without irinotecan improves progression-free and overall survival durations

By  

Inpharma, Vol. 1, Iss. 1609, 2007-01 ,pp. : 18-18

Adis International

Access to resources Recommend Favorite

Reply to progression-free survival: Does a correlation with survival justify its role as a surrogate clinical endpoint?

By Becker Andreas   Eichelberg Christian   Sun Maxine  

Cancer, Vol. 121, Iss. 11, 2015-06 ,pp. : 1906-1907

Blackwell Publishing

Access to resources Recommend Favorite